ocr: ireatment 0-0-00589 4-4-40Amg -0-0-0 Pactbe FIGURE 2A: Mean Change from Baseline in Total AUA la Symptom Score (0-35) Study 1 A 10- 10 13 LOCF (1-750) (-717)0-013) (n-665) (1-637) (0-619) 1-616) (-23) Duration of Treatment (weeks) indicates signilicant ditierence from placobo (pvalue $0.050). BaBaseline doterminod approocmately one woek prior to thei intial dose of doublo-bind modication at Week 0 Subsequent valuos aror observed cases. LOCF- Last obsorvation carried forward for pationts not comploting the 13-week study. Noter Pationts in the 081 mg treatmont group roceived 0.41 mg tor the firs ...
